Jenburkt Pharmaceuticals declared a final dividend of ₹20.70 (207%) per equity share for FY26 during its 41st Annual General Meeting held on September 4, 2026.

The meeting, conducted via video conference, saw shareholders approve the audited financial statements for the year ended March 31, 2026. The company reported growth in revenue and profitability while maintaining a debt-free and cash-rich position.

Key Resolutions Passed

Shareholders approved several ordinary and special resolutions during the AGM:

Governance and Compliance

The statutory auditors’ report and secretarial auditor’s report contained no adverse qualifications or reservations. M/s. Nilesh Shah & Associates served as the scrutinizer for the e-voting process.

Independent Director Krishnan Subharaman was absent due to travel. The Chairman addressed 46 shareholder questions covering financial results, product innovations, and market presence.

What the Numbers Show

The declaration of a 207% dividend yield underscores the company’s strong cash generation relative to its share capital. Combined with the management’s emphasis on a debt-free balance sheet, this suggests a capital allocation strategy focused on returning value to shareholders rather than aggressive reinvestment or leverage.

Jenburkt Pharmaceuticals has promoted Prem Ashish Bhuta to the position of Associate Vice President (AVP) – Strategic Initiatives. The elevation, approved by the Board of Directors via circulation on September 4, 2026, takes effect immediately.

Bhuta, who joined the company on July 13, 2021, moves up from his previous role as Management Associate. The appointment follows recommendations from the Nomination and Remuneration Committee and received prior approval from the Audit Committee. This move aligns with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Profile and Experience

Bhuta, aged 26, holds a Master of Science in Integrated Marketing from New York University and a Bachelor of Commerce (Honours) from Narsee Monjee Institute of Management Studies, Mumbai. He brings over five years of cross-functional experience across finance, sales, marketing operations, and business analytics within the pharmaceutical sector.

During his tenure at Jenburkt, Bhuta progressed through roles including Management Trainee and Officer – Finance. His responsibilities have spanned new product development, e-commerce, sales tracking, inventory management, and exposure to manufacturing processes.

Strategic Contributions

Bhuta was part of the core team that built ZIXA Strong, an OTC topical pain relief brand under the company’s wellness division. He also contributed to broader technology modernization efforts, including:

• Deployment of artwork management software
• Upgrade of the Laboratory Information Management System (LIMS)
• Rollout of a real-time sales tracking application used by a field force of over 700 employees

Prior to joining Jenburkt, Bhuta undertook strategic research projects with organizations such as Samsung Electronics America and Coca-Cola Southwest Beverages during his academic tenure in the United States.

Related Party Disclosure

The filing discloses that Bhuta is related to Ashish U. Bhuta, the Promoter and Chairman & Managing Director of Jenburkt Pharmaceuticals. The details of the appointment were filed with BSE Ltd. under Ref. No.: JPL/CS/2342/2026.